Pfizer’s Elrexfio accepted by SMC to treat relapsed and refractory multiple myeloma
Pfizer’s Elrexfio (elranatamab) has been accepted by the Scottish Medicines Consortium (SMC) for use as a monotherapy in adults with relapsed and refractory multiple myeloma. The BCMA-directed bispecific antibody will now be available on the NHS in …